Finding new treatments for lung cancer by targeting NSD3
Screening for inhibitors of NSD3 as a treatment for lung cancer
This study is looking for new medicines that can help fight aggressive lung cancer by blocking a protein called NSD3, and if successful, it could offer better treatment options for patients with this type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-11015921 on NIH RePORTER |
What this research studies
This research focuses on developing small molecule inhibitors that target the NSD3 protein, which has been linked to aggressive forms of lung cancer, particularly lung squamous cell carcinoma. The approach involves high throughput screening to identify potential inhibitors that can block the activity of NSD3, which is known to contribute to cancer progression. Patients may benefit from new therapeutic options if these inhibitors prove effective in treating lung cancer. The research utilizes advanced biochemical techniques to validate the effectiveness of these inhibitors in laboratory settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with lung squamous cell carcinoma or other cancers associated with NSD3 amplification.
Not a fit: Patients with lung cancer types not associated with NSD3 or those who do not have a confirmed diagnosis of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for patients with lung cancer, particularly those with aggressive forms linked to NSD3.
How similar studies have performed: While the specific inhibitors for NSD3 are novel and have not been reported before, similar approaches targeting oncogenes have shown promise in other cancer treatments.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Grembecka, Jolanta — University of Michigan at Ann Arbor
- Study coordinator: Grembecka, Jolanta
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.